Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal tract integrity refers to the capacity of the GI tract—particularly the epithelial and mucosal barriers—to maintain its selective permeability, allowing absorption of nutrients while preventing the translocation of harmful bacteria, toxins, and antigens. This integrity depends on complex molecular structures such as tight junction proteins (occludin, claudins, zonula occludens), the mucosal immune system, and the microbiota. Disruption of this barrier is implicated in multiple diseases, including inflammatory bowel diseases, infections, metabolic and autoimmune disorders, and may serve as a prognostic marker. Loss of GI tract integrity is not a molecular target itself, but rather the result of pathological changes affecting numerous molecular and cellular targets[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal tract integrity.